Respiratory Virus Infection Drugs Market

Published on 2023-01-07

Report Code: 1333

170 - 350 pages

Respiratory Virus Infection Drugs Market: By Drug Type (Antibiotics, Non-Steroidal Anti-Inflammatory Drugs [NSAIDS], Cough Suppressants, Nasal Decongestants), By Infection Type (Respiratory Syncytial Virus [RSV] Infection, Influenza & Parainfluenza Virus Infection, Adenovirus & Rhinovirus Infection), By Route of Administration (Oral, Parenteral), By Mode of Purchase (Prescription-Based Drugs, Over-the-Counter Drugs), By Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies, Clinics), And Region - Global Analysis of Market Size, Share & Trends For 2021-2022 And Forecasts To 2032

Buy Now

Add to cart

Table Of Content

1 Executive Summary
1.1. Regional Market Share
1.2. Business Trends
1.3. Respiratory Virus Infection Drugs Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot

2 Research Methodology
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation

3 Market Characteristics
3.1. Market Definition
3.2. Respiratory Virus Infection Drugs Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data

4 Respiratory Virus Infection Drugs Market – Industry Insights
4.1. Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability

5 Macroeconomic Indicators

6 Recent Developments

7 Market Dynamics
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends

8 Risk Analysis

9 Market Analysis
9.1. Porters Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological

10 Respiratory Virus Infection Drugs Market
10.1. Overview
10.2. Historical Analysis (2016-2020)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast

11 Respiratory Virus Infection Drugs Market Size & Forecast 2022A-2032F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Drug Type
11.3.1.1. Antibiotics
11.3.1.1.1 By Value (USD Million) 2022-2032F
11.3.1.1.2 Market Share (%) 2022-2032F
11.3.1.1.3 Y-o-Y Growth (%) 2022-2032F
11.3.1.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
11.3.1.2.1 By Value (USD Million) 2022-2032F
11.3.1.2.2 Market Share (%) 2022-2032F
11.3.1.2.3 Y-o-Y Growth (%) 2022-2032F
11.3.1.3. Cough Suppressants
11.3.1.3.1 By Value (USD Million) 2022-2032F
11.3.1.3.2 Market Share (%) 2022-2032F
11.3.1.3.3 Y-o-Y Growth (%) 2022-2032F
11.3.1.4. Nasal Decongestants
11.3.1.4.1 By Value (USD Million) 2022-2032F
11.3.1.4.2 Market Share (%) 2022-2032F
11.3.1.4.3 Y-o-Y Growth (%) 2022-2032F
11.3.1.5. Others
11.3.1.5.1 By Value (USD Million) 2022-2032F
11.3.1.5.2 Market Share (%) 2022-2032F
11.3.1.5.3 Y-o-Y Growth (%) 2022-2032F
11.3.2. By Infection Type
11.3.2.1. Respiratory Syncytial Virus (RSV) Infection
11.3.2.1.1 By Value (USD Million) 2022-2032F
11.3.2.1.2 Market Share (%) 2022-2032F
11.3.2.1.3 Y-o-Y Growth (%) 2022-2032F
11.3.2.2. Influenza Virus Infection
11.3.2.2.1 By Value (USD Million) 2022-2032F
11.3.2.2.2 Market Share (%) 2022-2032F
11.3.2.2.3 Y-o-Y Growth (%) 2022-2032F
11.3.2.3. Parainfluenza Virus Infection
11.3.2.3.1 By Value (USD Million) 2022-2032F
11.3.2.3.2 Market Share (%) 2022-2032F
11.3.2.3.3 Y-o-Y Growth (%) 2022-2032F
11.3.2.4. Adenovirus Infection
11.3.2.4.1 By Value (USD Million) 2022-2032F
11.3.2.4.2 Market Share (%) 2022-2032F
11.3.2.4.3 Y-o-Y Growth (%) 2022-2032F
11.3.2.5. Rhinovirus Infection
11.3.2.5.1 By Value (USD Million) 2022-2032F
11.3.2.5.2 Market Share (%) 2022-2032F
11.3.2.5.3 Y-o-Y Growth (%) 2022-2032F
11.3.2.6. Others
11.3.2.6.1 By Value (USD Million) 2022-2032F
11.3.2.6.2 Market Share (%) 2022-2032F
11.3.2.6.3 Y-o-Y Growth (%) 2022-2032F
11.3.3. By Route of Administration
11.3.3.1. Oral
11.3.3.1.1 By Value (USD Million) 2022-2032F
11.3.3.1.2 Market Share (%) 2022-2032F
11.3.3.1.3 Y-o-Y Growth (%) 2022-2032F
11.3.3.2. Parenteral
11.3.3.2.1 By Value (USD Million) 2022-2032F
11.3.3.2.2 Market Share (%) 2022-2032F
11.3.3.2.3 Y-o-Y Growth (%) 2022-2032F
11.3.4. By Mode of Purchase
11.3.4.1. Prescription-Based Drugs
11.3.4.1.1 By Value (USD Million) 2022-2032F
11.3.4.1.2 Market Share (%) 2022-2032F
11.3.4.1.3 Y-o-Y Growth (%) 2022-2032F
11.3.4.2. Over-the-Counter Drugs
11.3.4.2.1 By Value (USD Million) 2022-2032F
11.3.4.2.2 Market Share (%) 2022-2032F
11.3.4.2.3 Y-o-Y Growth (%) 2022-2032F
11.3.5. By Distribution Channel
11.3.5.1. Hospital Pharmacies
11.3.5.1.1 By Value (USD Million) 2022-2032F
11.3.5.1.2 Market Share (%) 2022-2032F
11.3.5.1.3 Y-o-Y Growth (%) 2022-2032F
11.3.5.2. Drug Stores
11.3.5.2.1 By Value (USD Million) 2022-2032F
11.3.5.2.2 Market Share (%) 2022-2032F
11.3.5.2.3 Y-o-Y Growth (%) 2022-2032F
11.3.5.3. Retail Pharmacies
11.3.5.3.1 By Value (USD Million) 2022-2032F
11.3.5.3.2 Market Share (%) 2022-2032F
11.3.5.3.3 Y-o-Y Growth (%) 2022-2032F
11.3.5.4. Clinics
11.3.5.4.1 By Value (USD Million) 2022-2032F
11.3.5.4.2 Market Share (%) 2022-2032F
11.3.5.4.3 Y-o-Y Growth (%) 2022-2032F
11.3.5.5. Others
11.3.5.5.1 By Value (USD Million) 2022-2032F
11.3.5.5.2 Market Share (%) 2022-2032F
11.3.5.5.3 Y-o-Y Growth (%) 2022-2032F

12 North America Respiratory Virus Infection Drugs Market Size & Forecast 2022A-2032F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Drug Type
12.3.2. By Infection Type
12.3.3. By Route of Administration
12.3.4. By Mode of Purchase
12.3.5. By Distribution Channel
12.4. Country
12.4.1. United States
12.4.2. Canada

13 Europe Respiratory Virus Infection Drugs Market Size & Forecast 2022A-2032F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Drug Type
13.3.2. By Infection Type
13.3.3. By Route of Administration
13.3.4. By Mode of Purchase
13.3.5. By Distribution Channel
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)

14 Asia Respiratory Virus Infection Drugs Market Size & Forecast 2022A-2032F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Drug Type
14.3.2. By Infection Type
14.3.3. By Route of Administration
14.3.4. By Mode of Purchase
14.3.5. By Distribution Channel
14.4. By Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC

15 Middle East and Africa Respiratory Virus Infection Drugs Market Size & Forecast 2022A-2032F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Drug Type
15.3.2. By Infection Type
15.3.3. By Route of Administration
15.3.4. By Mode of Purchase
15.3.5. By Distribution Channel
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa

16 Latin America Respiratory Virus Infection Drugs Market Size & Forecast 2022A-2032F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Drug Type
16.3.2. By Infection Type
16.3.3. By Route of Administration
16.3.4. By Mode of Purchase
16.3.5. By Distribution Channel
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America

17 Competitive Landscape
17.1. Company market share, 2021
17.2. Key player overview
17.3. Key stakeholders

18 Company Profiles
18.1. Johnson & Johnson
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1 Product Portfolio
18.1.4.2 Key Clients
18.1.4.3 Market Share
18.1.4.4 Recent News & Development (Last 3 Yrs.)
18.1.4.5 Executive Team
18.2. Roche Holding AG
18.3. Sanofi
18.4. GlaxoSmithKline plc
18.5. AstraZeneca
18.6. Merck & Co. Inc.
18.7. Boehringer Ingelheim International GmbH
18.8. Cipla Inc.
18.9. Gilead Sciences
18.10. Teva Pharmaceutical Industries Ltd.
18.11. Orion Corporation
18.12. Alnylam Pharmaceuticals
18.13. CHIESI Farmaceutici S.p.A.
18.14. Bavarian Nordic
18.15. ImmunoVaccine Technologies
18.16. Other Prominent Players